Rising Positivity Rates in Employment Screening Underscore Continued Market Growth for Drugs of Abuse Tests

Rising Positivity Rates in Employment Screening Underscore Continued Market Growth for Drugs of Abuse Tests

Quest Diagnostics recently announced the results of over 10 million drug tests it performed in the United States in 2014, including the continued reversal of a decades’ long trend of falling positivity rates for illicit substances in U.S. employment testing. Quest’s results from drug testing reinforce Kalorama Information’s expectation of a reinvigorated global market, led by the United States, for drugs of abuse test kits and reagents. In Drugs of Abuse Testing and Technologies Market, Kalorama Information summarized other market factors driving higher growth in the market:

The United States market is the largest [drugs of abuse testing market] due to several reasons including an increasing number of addictive prescription drugs on the U.S. market, U.S. federal government mandatory testing regimes, continued use of performance enhancing drugs in sports, emergence of new drugs and prevalence of methamphetamine abusers and acceptance of pre-employment and random employer drug testing.

Also, laxer enforcement of marijuana possession and increased usage of certain other recreational drugs has increased demand for drugs of abuse tests and reagents. Rising abuse of prescription narcotics has prompted the implementation of more safeguards in distribution and prescription, diverting users to heroin and other non-pharmaceutical narcotics.

The prevalence of drugs of abuse testing in the United States has supported extensive product diversification from core lab integrated chemistry platforms through point-of-care (POC) urine cups and saliva sample lateral flow tests. Drugs of abuse test panels, however, have solidified around the most prevalently used illicit drugs: marijuana followed by opiates, amphetamines, and cocaine. Quest Diagnostics’ drug testing index results for 2014 feature the same order in terms of positivity rates. The company made special note of the recent climb in cocaine positivity prevalence as well as longer-established trends of increasing use of heroin and amphetamines.

Despite declining positivity for MDMA in Quest’s testing, the recreational drug is among the leaders in terms of FDA approvals and CLIA complexity categorizations issued since the beginning of 2014 with 67 new test products and panel reagents. Positivity rates for PCP are relatively low and have not risen as appreciably as other drugs in recent years, but the drug too is well-represented in U.S. product introductions with 68 new test products categorized under CLIA since the beginning of 2014.

Kalorama Information’s Drugs of Abuse Testing and Technologies Market includes a worldwide review of market trends and issues, market projections, and market segmentation by sample (blood, hair, oral, urine), application/setting (criminal justice, employment, home/OTC, lab-based, professional POCT), world region, and leading industry suppliers.